ArticleBMC women's health2025
Rationality of FIGO 2018 IIIC cervical cancer according to local tumor and pelvic lymph node metastatic extent-a cohort study.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeThere is still controversy for FIGO 2018 stage IIIC. In order to better manage patients with stage IIIC. This study explored the prognostic performance of Stage IIIC patients according to the 2018 FIGO staging system.
methodsCervical cancer patients who underwent radical surgery or chemo-radiotherapy at our institute between June 2011 and June 2021 were retrospectively enrolled. Patients before year 2018 were re-staged according to the 2018 FIGO staging principle. Survival outcome was analyzed by Kaplan-Meier curves and compared using Log-rank method. The best cut-off values for the number of positive lymph nodes and the positive lymph node ratio (LNR) were obtained using X-tile software V3.6.1. The Cox proportional hazard regression model was used for multi-variable analysis.
resultsA total of 2553 cervical cancer patients were enrolled initially. Finally, 443 patients classified as 2018 FIGO stage III were included in the survival analysis.The 5-year disease-free survival (DFS) and 5-year overall survival (OS) of patients with stage IIIC2 were significantly poor than stage IIIA, IIIB and IIIC1, while IIIC1 patients had similar prognosis to IIIA/IIIB. For stage IIIC1 patients (n = 233), multivariate analysis showed that tumor size > 4 cm (DFS: HR 2.472, P < 0.001; OS: HR 2.368, P = 0.002) and poorly-differentiated histology (DFS: HR 2.158, P = 0.002; OS: HR 2.410, P = 0.002) were independent prognostic factors for reduced DFS and OS. In a subgroup analysis of IIIC1p women, tumor size > 4 cm (DFS: HR 2.658, P = 0.023; OS: HR 2.785, P = 0.039) and the number of positive pelvic lymph nodes(pLN) > 3 (DFS: HR 4.829, P < 0.001; OS: HR 5.614, P < 0.001) were found to be independent risk factors for reduced DFS and OS. Combining the local tumor size (TS) and pLN, patients with TS ≤ 4 cm + pLN ≤ 3 revealed significantly better 5-year DFS (89.2%) and 5-year OS (94.9%) than those with TS ≤ 4 cm + pLN > 3 and TS > 4 cm (P < 0.001). Moreover, stage IIIC1p patients with TS ≤ 4 cm + pLN ≤ 3 showed better DFS (P = 0.002) and OS (P = 0.001) than women with stage IIIA and IIIB.
conclusionThe survival outcomes for stage IIIC1 had similar prognosis for stage IIIA or IIIB in the current study. Patients with stage IIIC1p showed variable prognoses dependent on local tumor size and the extent of pelvic lymph node metastases. Therefore, the existing staging criteria might be further improved to provide better guidance for individualized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.